HAYWARD, CA, United States
HAYWARD, CA, United States

Time filter

Source Type

Patent
Aradigm Corporation and Oregon State University | Date: 2016-11-28

Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.


Patent
Aradigm Corporation | Date: 2016-10-20

A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions.


Patent
Aradigm Corporation | Date: 2015-04-01

A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions.


A method of diagnosing respiratory fluid in a patient suffering from gastro esophageal reflux disease (GERD) is disclosed. The method comprises (1) orally administering to a subject suspected of suffering from gastro esophageal reflux disease (GERD), a formulation comprised of a plurality of particles comprised of a biocompatible polymer (e.g. carnauba wax) and a detectable, non-radioactive label (e.g. a fluorescent label), (2) allowing the formulation to remain in the subject over a period of time during which the subject would be expected to aspirate the formulation, (3) collecting respiratory fluid from the subject, and (4) analyzing the respiratory fluid to determine if the fluid contains the detectable label, and thereby determining if the subject regurgitates fluid into the respiratory tract. Alternatively, or additionally, a subject swallows a label that is not destroyed in the respiratory tract, or in the gastrointestinal tract, which further has the property that it is absorbed from the respiratory tract but not from the gastrointestinal tract. The presence of the label is then analyzed in blood, or, if the substance is excreted from blood to urine, in urine samples. The qualitative analysis can be also expanded into quantitative analysis, enabling the estimation of either the concentration, or the amount, or both, of the gastrointestinal contents that entered the respiratory tract.


Patent
Aradigm Corporation | Date: 2016-07-25

An aerosolizable formulation comprised of a drug, a carrier and pH affecting component is disclosed. The drug is dissolved in the formulation at a concentration above which it remains in solution at neutral pH. This increases the concentration of the drug in solution making it possible to administer larger amounts of drug with the same or a smaller volume of formulation. When the formulation is aerosolized to small particles and inhaled into human lungs in small volumes (e.g. 0.05 to 0.5 mL) the fluids in the lungs neutralize the formulation causing the drug to participate out of solution. This results in the drug being delivered at a controlled rate below the rate at which drug is administered from a formulation initially at a neutral pH.


Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.


A method of diagnosing in a subject for the purpose of determining if the subjects gastrointestinal contents has entered the subjects respiratory tract. The qualitative analysis can be also expanded into quantitative analysis, enabling the estimation of either the concentration, or the amount, or both, of the gastrointestinal contents that entered the respiratory tract. The invention also provides methods of treatment based on the identification of aspiration using the methods of the invention.


Methods for formulating a liposome comprised of a surfactant and a cryopreservative that can be frozen for long term stability, and upon thawing provides an immediate and sustained release delivery profile. Specific liposome formulations include anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.


Patent
Aradigm Corporation and Oregon State University | Date: 2015-03-31

Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.


Patent
Aradigm Corporation | Date: 2016-01-12

A formulation is disclosed which is comprised of a first solvent having a first active ingredient dissolved therein a plurality of microenvironments dispersed in the first solvent, the microenvironment being comprised of a shell having a dimension in a range of 50 nanometers to 100, the shell comprising an internal volume comprising a second solvent having a second active ingredient dissolved therein and nanocrystals of the second active ingredient.

Loading Aradigm Corporation collaborators
Loading Aradigm Corporation collaborators